Business
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026. The PIPE financing consisted of an aggregate of 2,502,696 shares o
About this update from Polaryx Therapeutics, Inc.
[{"type":"image","alt":"Polaryx Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Polaryx Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dphdMdM6dqfB6z52pG.7yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32","width":300,"height":50},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dphdMdM6dqfB6z52pG.7yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32","width":300,"height":50}},"lazy":false},{"type":"text","content":"PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026.","length":433,"tagName":"p"},{"type":"text","content":"The PIPE financing consisted of an aggregate of 2,502,696 shares of common stock at an average purchase price of approximately $4.00 per share.","length":143,"tagName":"p"},{"type":"text","content":"Polaryx intends to use the net proceeds from the PIPE financing, together with existing cash and cash equivalents, to fund the initiation of the Phase 2 SOTERIA trial, evaluating PLX-200 across multiple LSD indications, through key planned clinical milestones along with the continued research and development of its product candidates, as well as for working capital and general corporate purposes.","length":399,"tagName":"p"},{"type":"text","content":"“We are grateful for the confidence expressed by our new and existing investors for their support in Polaryx’s mission to meet the large unmet need for patients and families living with lysosomal storage disorders. Polaryx has now secured the capital necessary to transition into clinical execution mode,” said Alex Yang, Chief Executive Officer of Polaryx. “This financing provides us with the runway to launch and reach key anticipated clinical milestones within the SOTERIA ...